Stanford University School of medicine scientists have completed phase 3 testing of the antiviral drug remdesivir. It was made with a comparison of the 5-day treatment program clinical effectiveness with a 10-day course. To provide medical professionals with enough medication to treat patients, this test is essentially important in terms of the pandemic.
The second goal of the study was to compare adverse events at the different treatment periods.
The study found that the 5-day course of remdesivir leads to the same clinical improvement as a 10-day course. In the 5-day group, the time to clinical improvements for 50% of patients was 10 days. In the 10-day group, the same indicator was 11 days. By day 14, 60% of patients from the 5-day group with 52.3% of patients from the 10-day group were discharged. 64.5% of patients in the 5-day group and 53.8% – in the 10-day group achieved clinical recovery on day 14.
The drug was generally well tolerated by patients in both groups. The most common side effects were nausea (10% – in the 5-day group, 8.6% – in the 10-day group). There was also acute respiratory failure (6% – in the 5-day group, 10.7% in the 10-day group). In both groups, the level of liver enzyme (LEL) has been increased in 7.3% of cases.
Scientists are generally satisfied with the obtained results. “These data are encouraging as they indicate that patients who received a shorter, 5-day course of remdesivir experienced similar clinical improvement as patients who received a 10-day treatment course,” said Aruna Subramanian, MD, Clinical Professor of Medicine, Chief, Immunocompromised Host Infectious Diseases, Stanford University School of Medicine.
Useful article, necessary information? Share it!
Someone will also find it useful and necessary:
